康希諾生物(06185.HK)夥印尼Etana戰略合作 加速推進吸入用新冠疫苗與結核病疫苗技術研發
康希諾生物(06185.HK)宣布,日前與印尼生物製藥公司Etana簽署創新疫苗研發戰略合作協定,與來自兩國的結核病及呼吸道傳染病科學家開展技術合作,加速推進吸入用新冠疫苗與結核病疫苗技術的研發。
印尼衛生部長布迪.古納迪.薩迪金表示,希望可以和康希諾進行更深層次的合作,通過技術轉移、當地語系化生產等模式引進更多創新產品,兩國團結抗疫與復甦發展注入強勁動力。
目前,康希諾生物吸入用疫苗技術已應用於新冠疫苗領域。公司成功研發的全球首款吸入用新冠疫苗於今年獲得中國緊急使用授權,並已在上海、江蘇、天津等地展開接種。此外,該創新疫苗於近日獲得摩洛哥緊急使用許可,將進一步拓展海外市場,為全球公共衛生事業做出貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.